Priya Begani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Priya Begani has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Akshay Narkar
Department of Cancer Biology, The University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS, USA
1 shared publicationAlejandro Parrales
Department of Cancer Biology, The University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS, USA
1 shared publicationAmit S. Adhikari
Center for Advanced Preclinical Research, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA
1 shared publicationDavid T Hughes
Department of Surgery, Division of Endocrine Surgery, Michigan Medicine, Ann Arbor, Michigan
1 shared publicationGregory J Basura
Department of Otolaryngology-Head and Neck Surgery, Kresge Hearing Research Institute, Michigan Medicine, Ann Arbor, Michigan
1 shared publication- Katherine Wolf
Department of Internal Medicine, Division of Metabolism, Endocrinology, & Diabetes, Endocrine Oncology Program, Michigan Medicine, Ann Arbor, MI, United States
1 shared publication
Latest Publications
- Open Access
- 5 September 2019
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (11) , 2151-2157
A Family With a Carotid Body Paraganglioma and Thyroid Neoplasias With a New SDHAF2 Germline Variant
At least 30% of all pheochromocytomas/paragangliomas (PCCs/PGLs) arise in patients with a germline predisposition syndrome. Variants in succinate dehydrogenase subunits A, B, C, and D (SDHA, SDHB, SDHC, and SDHD) are the most common pathogenic germline alterations. Only very few pathogenic variants have been reported in succinate dehydrogenase assembly factor 2 (SDHAF2). Here, we describe a 30-year old female patient who presented with a left-sided neck mass, which was later characterized as a carotid body paraganglioma. Genetic testing revealed a likely pathogenic SDHAF2 variant (c.347G>A;p.W116X). Two sisters carried the same pathologic variant and screening protocols were recommended. Whole body magnetic resonance imaging revealed thyroid nodules, which were followed by fine needle aspiration that confirmed papillary thyroid carcinoma in one sister and a follicular adenoma in the other, which led to a hemithyroidectomy and total thyroidectomy, respectively. As evidence for pathogenic variants in SDHAF2 causing predisposition to PCC/PGL is limited, we discuss the challenges in mutational variant interpretation and decision making regarding screening for associated tumors.
- 5 September 2019
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (11) , 2151-2157
Open AccessA Family With a Carotid Body Paraganglioma and Thyroid Neoplasias With a New SDHAF2 Germline Variant
At least 30% of all pheochromocytomas/paragangliomas (PCCs/PGLs) arise in patients with a germline predisposition syndrome. Variants in succinate dehydrogenase subunits A, B, C, and D (SDHA, SDHB, SDHC, and SDHD) are the most common pathogenic germline alterations. Only very few pathogenic variants have been reported in succinate dehydrogenase assembly factor 2 (SDHAF2). Here, we describe a 30-year old female patient who presented with a left-sided neck mass, which was later characterized as a carotid body paraganglioma. Genetic testing revealed a likely pathogenic SDHAF2 variant (c.347G>A;p.W116X). Two sisters carried the same pathologic variant and screening protocols were recommended. Whole body magnetic resonance imaging revealed thyroid nodules, which were followed by fine needle aspiration that confirmed papillary thyroid carcinoma in one sister and a follicular adenoma in the other, which led to a hemithyroidectomy and total thyroidectomy, respectively. As evidence for pathogenic variants in SDHAF2 causing predisposition to PCC/PGL is limited, we discuss the challenges in mutational variant interpretation and decision making regarding screening for associated tumors.
- Open Access
- 16 December 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (5) , 5401-5415
Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities
Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities
- 16 December 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (5) , 5401-5415
Open AccessAllele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities
Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities